EE04237B1 - 4-(5-metüül-3-fenüülisoksasool-4-üül)benseensulfoonamiidi kristalliline vorm, selle kasutamine ja valmistamise meetod - Google Patents

4-(5-metüül-3-fenüülisoksasool-4-üül)benseensulfoonamiidi kristalliline vorm, selle kasutamine ja valmistamise meetod

Info

Publication number
EE04237B1
EE04237B1 EEP199900053A EE9900053A EE04237B1 EE 04237 B1 EE04237 B1 EE 04237B1 EE P199900053 A EEP199900053 A EE P199900053A EE 9900053 A EE9900053 A EE 9900053A EE 04237 B1 EE04237 B1 EE 04237B1
Authority
EE
Estonia
Prior art keywords
phenylisoxazol
benzenesulfonamide
methyl
preparation
crystalline form
Prior art date
Application number
EEP199900053A
Other languages
English (en)
Estonian (et)
Other versions
EE9900053A (et
Inventor
J. Talley John
R. Medich John
T. Mclaughlin Kathleen
T. Gaud Henry
E. Yonan Edward
Original Assignee
G.D. Searle & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G.D. Searle & Co. filed Critical G.D. Searle & Co.
Priority to EEP200400073A priority Critical patent/EE200400073A/xx
Publication of EE9900053A publication Critical patent/EE9900053A/xx
Publication of EE04237B1 publication Critical patent/EE04237B1/xx

Links

Classifications

    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10W—GENERIC PACKAGES, INTERCONNECTIONS, CONNECTORS OR OTHER CONSTRUCTIONAL DETAILS OF DEVICES COVERED BY CLASS H10
    • H10W40/00—Arrangements for thermal protection or thermal control
    • H10W40/60—Securing means for detachable heating or cooling arrangements, e.g. clamps
    • H10W40/611—Bolts or screws
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10W—GENERIC PACKAGES, INTERCONNECTIONS, CONNECTORS OR OTHER CONSTRUCTIONAL DETAILS OF DEVICES COVERED BY CLASS H10
    • H10W40/00—Arrangements for thermal protection or thermal control
    • H10W40/70—Fillings or auxiliary members in containers or in encapsulations for thermal protection or control
    • H10W40/73—Fillings or auxiliary members in containers or in encapsulations for thermal protection or control for cooling by change of state

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Liquid Crystal Substances (AREA)
EEP199900053A 1996-08-14 1997-08-12 4-(5-metüül-3-fenüülisoksasool-4-üül)benseensulfoonamiidi kristalliline vorm, selle kasutamine ja valmistamise meetod EE04237B1 (et)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EEP200400073A EE200400073A (et) 1996-08-14 1997-08-12 4-(5-metüül-3-fenüülisoksasool-4-üül)benseensulfoonamiidi kristalliline vorm ja selle kasutamine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2437896P 1996-08-14 1996-08-14
PCT/US1997/015126 WO1998006708A1 (en) 1996-08-14 1997-08-12 Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide

Publications (2)

Publication Number Publication Date
EE9900053A EE9900053A (et) 1999-08-16
EE04237B1 true EE04237B1 (et) 2004-02-16

Family

ID=21820280

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900053A EE04237B1 (et) 1996-08-14 1997-08-12 4-(5-metüül-3-fenüülisoksasool-4-üül)benseensulfoonamiidi kristalliline vorm, selle kasutamine ja valmistamise meetod

Country Status (38)

Country Link
US (2) US6441014B2 (sr)
EP (2) EP1283203A1 (sr)
JP (2) JP3631763B2 (sr)
KR (1) KR100383148B1 (sr)
CN (1) CN1205193C (sr)
AP (1) AP1055A (sr)
AR (1) AR009244A1 (sr)
AT (1) ATE228117T1 (sr)
AU (1) AU722072B2 (sr)
BG (1) BG64259B1 (sr)
BR (1) BR9711151A (sr)
CA (1) CA2264104A1 (sr)
CZ (1) CZ297679B6 (sr)
DE (1) DE69717281T2 (sr)
DK (1) DK0920422T3 (sr)
EA (2) EA003754B1 (sr)
EE (1) EE04237B1 (sr)
ES (1) ES2188971T3 (sr)
GE (1) GEP20022636B (sr)
HU (1) HUP0400923A3 (sr)
IL (2) IL161224A0 (sr)
IS (1) IS1989B (sr)
LT (1) LT4551B (sr)
LV (1) LV12274B (sr)
NO (1) NO312461B1 (sr)
NZ (1) NZ334132A (sr)
OA (1) OA11298A (sr)
PL (1) PL191313B1 (sr)
PT (1) PT920422E (sr)
RO (1) RO120771B1 (sr)
RS (1) RS49671B (sr)
SI (1) SI9720059B (sr)
SK (1) SK283558B6 (sr)
TR (1) TR199900298T2 (sr)
TW (1) TW527350B (sr)
UA (1) UA52684C2 (sr)
WO (1) WO1998006708A1 (sr)
ZA (1) ZA977314B (sr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU722072B2 (en) * 1996-08-14 2000-07-20 G.D. Searle & Co. Crytalline form of 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide
NZ333399A (en) 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
GB9810920D0 (en) * 1998-05-21 1998-07-22 Merck Sharp & Dohme Therapeutic use
ATE315033T1 (de) * 1998-08-07 2006-02-15 Chiron Corp Subtituierte isoxazole derivate als estrogen rezeptor modulatore
WO2000029022A1 (en) * 1998-11-12 2000-05-25 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with centrally acting analgesics
AU3384200A (en) * 1999-03-01 2000-09-21 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and a selective cox-2 inhibitor drug
EA006598B1 (ru) * 1999-08-20 2006-02-24 Орто-Макнейл Фармасьютикал, Инк. Композиция, содержащая трамадол и противосудорожное лекарственное средство
CA2381895A1 (en) * 1999-08-27 2001-03-08 Merck & Co., Inc. Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome
WO2001041760A2 (en) 1999-12-08 2001-06-14 Pharmacia Corporation Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
DE10032132A1 (de) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
EP2332934B1 (en) 2001-08-15 2017-03-01 Pharmacia & Upjohn Company LLC Processes for the preparation of crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide.
US20070072921A1 (en) * 2002-07-26 2007-03-29 Talley John J Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide
AU2003238668A1 (en) 2003-04-04 2004-10-25 Hetero Drugs Limited Novel crystalline forms of valdecoxib
JP4354984B2 (ja) 2003-05-07 2009-10-28 オステオロジックス エイ／エス 水溶性ストロンチウム塩を用いる軟骨／骨症状の治療
US20050182113A1 (en) * 2003-12-30 2005-08-18 Venkataraman Sundaram Method for preparing diaryl-substituted isoxazole compounds
US20050272787A1 (en) * 2004-05-19 2005-12-08 Eswaraiah Sajja Process for preparing crystalline form A of valdecoxib
WO2005120499A1 (en) * 2004-06-10 2005-12-22 Chandiran Thakashinamoorthy Form a of valdecoxib suitable for pharmaceutical formulations
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
DK1612203T3 (da) * 2004-06-28 2007-12-03 Gruenenthal Gmbh Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid
KR100591786B1 (ko) 2004-10-19 2006-06-26 휴먼팜 주식회사 프란루카스트를 함유하는 약학적 조성물 및 이의 제조 방법
KR20080012360A (ko) 2005-05-20 2008-02-11 얀센 파마슈티카 엔.브이. 설파미드 유도체의 제조 방법
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
EA200870556A1 (ru) 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. Комбинированная терапия в лечении эпилепсии и родственных расстройств
BRPI0915890A2 (pt) 2008-06-23 2015-11-03 Janssen Pharmaceutica Nv forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN103172583A (zh) * 2013-03-07 2013-06-26 深圳市资福药业有限公司 一种制备帕瑞昔布的方法
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
US10028904B2 (en) 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
CN114441666B (zh) * 2020-11-05 2024-02-27 成都百裕制药股份有限公司 一种4-(5-甲基-3-苯基-4-异恶唑)苯磺酰氯中杂质的检测方法
US20240165148A1 (en) 2021-03-15 2024-05-23 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
PL185544B1 (pl) * 1995-02-13 2003-05-30 Nowa pochodna podstawionego izoksazolu i środek farmaceutyczny
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
AU722072B2 (en) * 1996-08-14 2000-07-20 G.D. Searle & Co. Crytalline form of 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide
AU2003238668A1 (en) * 2003-04-04 2004-10-25 Hetero Drugs Limited Novel crystalline forms of valdecoxib
US20050272787A1 (en) * 2004-05-19 2005-12-08 Eswaraiah Sajja Process for preparing crystalline form A of valdecoxib

Also Published As

Publication number Publication date
NZ334132A (en) 2000-06-23
EA003754B1 (ru) 2003-08-28
GEP20022636B (en) 2002-02-25
US7135489B2 (en) 2006-11-14
US6441014B2 (en) 2002-08-27
US20030004200A1 (en) 2003-01-02
US20010003752A1 (en) 2001-06-14
JP2005015497A (ja) 2005-01-20
IL128255A0 (en) 1999-11-30
LV12274B (en) 1999-09-20
CN1233243A (zh) 1999-10-27
AP1055A (en) 2002-04-04
CZ297679B6 (cs) 2007-03-07
SK13699A3 (en) 1999-07-12
EA199900200A1 (ru) 1999-06-24
EA200000891A1 (ru) 2001-02-26
NO312461B1 (no) 2002-05-13
EA001472B1 (ru) 2001-04-23
KR20000029994A (ko) 2000-05-25
JP3631763B2 (ja) 2005-03-23
LV12274A (lv) 1999-05-20
KR100383148B1 (ko) 2003-05-09
AP9901458A0 (en) 1999-03-31
ES2188971T3 (es) 2003-07-01
SI9720059B (sl) 2011-11-30
YU7499A (sh) 2000-03-21
DE69717281D1 (de) 2003-01-02
BG103155A (bg) 1999-11-30
PT920422E (pt) 2003-03-31
WO1998006708A1 (en) 1998-02-19
HUP0400923A3 (en) 2007-11-28
DK0920422T3 (da) 2003-03-17
HK1023125A1 (en) 2000-09-01
BR9711151A (pt) 1999-08-17
EP0920422A1 (en) 1999-06-09
CN1205193C (zh) 2005-06-08
DE69717281T2 (de) 2003-09-04
AU722072B2 (en) 2000-07-20
SK283558B6 (sk) 2003-09-11
LT4551B (lt) 1999-10-25
EP1283203A1 (en) 2003-02-12
LT99024A (en) 1999-07-26
EE9900053A (et) 1999-08-16
IL161224A0 (en) 2004-09-27
AR009244A1 (es) 2000-04-12
ZA977314B (en) 1998-08-14
EP0920422B1 (en) 2002-11-20
OA11298A (en) 2003-10-22
TW527350B (en) 2003-04-11
TR199900298T2 (xx) 1999-05-21
PL191313B1 (pl) 2006-04-28
IS4961A (is) 1999-01-29
CA2264104A1 (en) 1998-02-19
PL331607A1 (en) 1999-08-02
UA52684C2 (uk) 2003-01-15
BG64259B1 (bg) 2004-07-30
IS1989B (is) 2005-02-15
CZ33499A3 (cs) 1999-06-16
SI9720059A (sl) 1999-12-31
NO990541D0 (no) 1999-02-05
JP2000506542A (ja) 2000-05-30
RS49671B (sr) 2007-11-15
NO990541L (no) 1999-02-05
HUP0400923A2 (hu) 2004-08-30
AU4093697A (en) 1998-03-06
IL128255A (en) 2004-06-20
ATE228117T1 (de) 2002-12-15
RO120771B1 (ro) 2006-07-28

Similar Documents

Publication Publication Date Title
EE04237B1 (et) 4-(5-metüül-3-fenüülisoksasool-4-üül)benseensulfoonamiidi kristalliline vorm, selle kasutamine ja valmistamise meetod
EE9800437A (et) N-[4-(heteroarüülmetüül)fenüül]-heteroarüülamiinid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetod selle valmistamiseks
FI962494L (fi) 5-(2-imidatsolinyyliamino)bentsimidatsolijohdannaisia, niiden valmistus ja niiden käyttö alpha-2-adrenoseptoriagonisteina
NO20005265D0 (no) Substituerte benzamider, deres fremstilling og anvendelse som inhibitorer av cystin-proteaser
EE9700328A (et) Tahke oraalne preparaat, mis sisaldab toimeainena olansapiini, selle valmistamismeetod ja kasutamine
EE200300237A (et) Difenüülasetidinooni derivaadid, nende kasutamine, ravim ja selle valmistamismeetod
EE200300238A (et) Difenüülasetidinooni derivaadid, nende kasutamine, ravim ja selle valmistamismeetod
NO991815L (no) Oksadiazoler, fremgangsmÕter for deres fremstilling og deres anvendelse som medikamenter
EE200100323A (et) (Hetero)arüüli - bitsüklilise heteroarüüli derivaadid, nende valmistamine ja nende kasutamine proteaasiinhibiitoritena
BR9810829B1 (pt) composto heterocìclico, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica.
EE05387B1 (et) KinasoliiniÁderivaadid,ÁnendeÁvalmistamismeetodÁjaÁkasutamine
NO20011956D0 (no) Substituerte fenylderivater, deres fremstilling og anvendelse
NO20000294L (no) Derivater av acylpiperazinylpyrimidiner, deres fremstilling og anvendelse som legemidler
EE200100653A (et) Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine
DE50112123D1 (de) Retard-zubereitungen von chinolon-antibiotika und verfahren zu ihrer herstellung
NO20022021D0 (no) Indeno-, nafto- og benzocyklohepta-dihydrotiazolderivater, fremstilling av de samme og deres anvendelse somanoreksilegemidler
EE200100314A (et) Meetod farmatseutilise kompositsiooni valmistamiseks, farmatseutiline kompositsioon ja selle kasutamine
EE05187B1 (et) Hirudiini prekursor, selle kasutamine ja meetod Leu-hirudiini valmistamiseks
EE200000099A (et) Antimükootiline kompositsioon, selle kasutamine ja valmistamismeetod ning antimükootiline toode
EE03387B1 (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks
EE04770B1 (et) Tritsüklilised delta3-piperidiinid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
EE200100305A (et) Preparaat, selle kasutamine ja valmistamismeetod
EE9900311A (et) Söödalisandi valmistamise meetod, söödalisand ja selle kasutamine
EE04260B1 (et) Farmatseutiline kompositsioon, selle valmistamisemeetod ja kasutamine
EE200200637A (et) Torasemiidi uudne polümorf V, selle valmistamismeetod, kasutamine ja ravimvorm

Legal Events

Date Code Title Description
AA1Y Spc filed

Free format text: PRODUCT NAME: BEXTRA; REG NO/DATE: 009930 13.06.2003 RA 009931 13.06.2003 RA 009932 13.06.2003

Spc suppl protection certif: C20040001

Filing date: 20040429

HE1A Change of address
FG1Y Spc granted

Free format text: PRODUCT NAME: BEXTRA; REG NO/DATE: 414903 06.06.2003 MUEUEGILUBA NR 415003 06.06.2003 MUEUEGILUBANR 415103 06.06.2003

Spc suppl protection certif: C20040001 00005

Filing date: 20040429

Extension date: 20180606

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20090812

MC1Y Annulment of an spc

Spc suppl protection certif: 00005